
Korro Bio is a biopharmaceutical company with a mission to discover, develop and commercialize a new class of genetic medicines based on editing RNA, enabling treatment of both rare and highly prevalent diseases.
Korro Bio revenue
Korro Bio's annual revenue was $6.4M in December 2025 (Stock Analysis). That is up 181% from $2.3M a year earlier.
All 2 revenue readings, with sources
| As of | Revenue | Source |
|---|---|---|
| Dec 2024 | $2.3M | Stock Analysis |
| Dec 2025 | $6.4M | Stock Analysis |
Korro Bio market cap
Korro Bio is a public company. Its market capitalisation was $140M in September 2026.
Korro Bio CEO
Kieron Burrows is CEO of Korro Bio.
Korro Bio FAQ
What is Korro Bio's revenue?
Korro Bio's annual revenue was $6.4M in December 2025, according to Stock Analysis.
Is Korro Bio publicly traded?
Yes. Korro Bio is a public company, with a market capitalisation of $140M in September 2026.
Who is the CEO of Korro Bio?
Kieron Burrows is the CEO of Korro Bio.
Categories
How this page is sourced
2 from public sources. Founder figures link to the second they were said; public figures name their source; estimates are marked EST and say whose they are. Not financial advice.
Updated Sep 28, 2026Data disclaimerReport a correctionClaim this profileRun Korro Bio? Join the podcast